287 related articles for article (PubMed ID: 29588430)
1. An Engineered Complement Factor H Construct for Treatment of C3 Glomerulopathy.
Yang Y; Denton H; Davies OR; Smith-Jackson K; Kerr H; Herbert AP; Barlow PN; Pickering MC; Marchbank KJ
J Am Soc Nephrol; 2018 Jun; 29(6):1649-1661. PubMed ID: 29588430
[No Abstract] [Full Text] [Related]
2. Efficacy of GalNAc C3 siRNAs in factor H-deficient mice with C3 glomerulopathy.
Zanchi C; Locatelli M; Cerullo D; Aumiller V; Corna D; Rottoli D; Schubert S; Noris M; Tomasoni S; Remuzzi G; Zoja C; Benigni A
Mol Immunol; 2024 Apr; 168():10-16. PubMed ID: 38368725
[TBL] [Abstract][Full Text] [Related]
3. Liver factor B silencing to cure C3 glomerulopathy: Evidence from a mouse model of complement dysregulation.
Zanchi C; Locatelli M; Corna D; Cerullo D; Fishilevich E; Desai D; Rottoli D; Donadelli R; Noris M; Zoja C; Remuzzi G; Benigni A
Mol Immunol; 2023 Sep; 161():25-32. PubMed ID: 37481826
[TBL] [Abstract][Full Text] [Related]
4. Homodimeric Minimal Factor H:
Kamala O; Malik TH; Hallam TM; Cox TE; Yang Y; Vyas F; Luli S; Connelly C; Gibson B; Smith-Jackson K; Denton H; Pappworth IY; Huang L; Kavanagh D; Pickering MC; Marchbank KJ
Front Immunol; 2021; 12():752916. PubMed ID: 34956184
[TBL] [Abstract][Full Text] [Related]
5. von Willebrand factor variants in C3 glomerulopathy: A Chinese cohort study.
Chen YY; Han SS; Cao Y; Yu XJ; Zhu L; Luo JC; Song WC; Yu F; Mao YH; Zhao MH
Clin Immunol; 2021 Aug; 229():108794. PubMed ID: 34245915
[TBL] [Abstract][Full Text] [Related]
6. Characterization of C3 in C3 glomerulopathy.
Sethi S; Vrana JA; Fervenza FC; Theis JD; Sethi A; Kurtin PJ; Zhang Y; Smith RJH
Nephrol Dial Transplant; 2017 Mar; 32(3):459-465. PubMed ID: 27507892
[TBL] [Abstract][Full Text] [Related]
7. Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.
Noris M; Donadelli R; Remuzzi G
Pediatr Nephrol; 2019 Aug; 34(8):1311-1323. PubMed ID: 29948306
[TBL] [Abstract][Full Text] [Related]
8. Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.
Donadelli R; Pulieri P; Piras R; Iatropoulos P; Valoti E; Benigni A; Remuzzi G; Noris M
Front Immunol; 2018; 9():2329. PubMed ID: 30487789
[TBL] [Abstract][Full Text] [Related]
9. Selective Binding of Heparin/Heparan Sulfate Oligosaccharides to Factor H and Factor H-Related Proteins: Therapeutic Potential for C3 Glomerulopathies.
Loeven MA; Maciej-Hulme ML; Yanginlar C; Hubers MC; Kellenbach E; de Graaf M; van Kuppevelt TH; Wetzels J; Rabelink TJ; Smith RJH; van der Vlag J
Front Immunol; 2021; 12():676662. PubMed ID: 34489931
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Targeted Complement Inhibition in Experimental C3 Glomerulopathy.
Ruseva MM; Peng T; Lasaro MA; Bouchard K; Liu-Chen S; Sun F; Yu ZX; Marozsan A; Wang Y; Pickering MC
J Am Soc Nephrol; 2016 Feb; 27(2):405-16. PubMed ID: 26047789
[TBL] [Abstract][Full Text] [Related]
11. An engineered construct combining complement regulatory and surface-recognition domains represents a minimal-size functional factor H.
Hebecker M; Alba-Domínguez M; Roumenina LT; Reuter S; Hyvärinen S; Dragon-Durey MA; Jokiranta TS; Sánchez-Corral P; Józsi M
J Immunol; 2013 Jul; 191(2):912-21. PubMed ID: 23772024
[TBL] [Abstract][Full Text] [Related]
12. Combination of factor H mutation and properdin deficiency causes severe C3 glomerulonephritis.
Lesher AM; Zhou L; Kimura Y; Sato S; Gullipalli D; Herbert AP; Barlow PN; Eberhardt HU; Skerka C; Zipfel PF; Hamano T; Miwa T; Tung KS; Song WC
J Am Soc Nephrol; 2013 Jan; 24(1):53-65. PubMed ID: 23204401
[TBL] [Abstract][Full Text] [Related]
13. Factor H-Related Protein 1 Drives Disease Susceptibility and Prognosis in C3 Glomerulopathy.
Márquez-Tirado B; Gutiérrez-Tenorio J; Tortajada A; Lucientes Continente L; Caravaca-Fontán F; Malik TH; Roldán Montero R; Elías S; Saiz Gonzalez A; Fernández-Juarez G; Sánchez-Corral P; Pickering MC; Praga M; Rodríguez de Córdoba S; Goicoechea de Jorge E
J Am Soc Nephrol; 2022 Jun; 33(6):1137-1153. PubMed ID: 35545301
[TBL] [Abstract][Full Text] [Related]
14. Different Aspects of Classical Pathway Overactivation in Patients With C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis.
Michels MAHM; van de Kar NCAJ; van Kraaij SAW; Sarlea SA; Gracchi V; Engels FAPT; Dorresteijn EM; van der Deure J; Duineveld C; Wetzels JFM; van den Heuvel LPWJ; Volokhina EB
Front Immunol; 2021; 12():715704. PubMed ID: 34456924
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Small Interfering RNA Targeting Complement C3 in a Mouse Model of C3 Glomerulopathy.
Zanchi C; Locatelli M; Cerullo D; Aumiller V; Corna D; Rottoli D; Eisermann M; Donadelli R; Mousavi M; Noris M; Remuzzi G; Benigni A; Zoja C
J Immunol; 2022 Apr; 208(7):1772-1781. PubMed ID: 35277417
[TBL] [Abstract][Full Text] [Related]
16. Gain-of-function factor H-related 5 protein impairs glomerular complement regulation resulting in kidney damage.
Malik TH; Gitterman DP; Lavin DP; Lomax-Browne HJ; Hiemeyer EC; Moran LB; Boroviak K; Cook HT; Gilmore AC; Mandwie M; Ahmad A; Alexander IE; Logan GJ; Marchbank KJ; Bradley A; Pickering MC
Proc Natl Acad Sci U S A; 2021 Mar; 118(13):. PubMed ID: 33753502
[TBL] [Abstract][Full Text] [Related]
17. Humanized C3 Mouse: A Novel Accelerated Model of C3 Glomerulopathy.
Devalaraja-Narashimha K; Meagher K; Luo Y; Huang C; Kaplan T; Muthuswamy A; Halasz G; Casanova S; O'Brien J; Peyser Boiarsky R; McWhirter J; Gartner H; Bai Y; MacDonnell S; Liu C; Hu Y; Latuszek A; Wei Y; Prasad S; Huang T; Yancopoulos G; Murphy A; Olson W; Zambrowicz B; Macdonald L; Morton LG
J Am Soc Nephrol; 2021 Jan; 32(1):99-114. PubMed ID: 33288630
[TBL] [Abstract][Full Text] [Related]
18. Partial Complement Factor H Deficiency Associates with C3 Glomerulopathy and Thrombotic Microangiopathy.
Vernon KA; Ruseva MM; Cook HT; Botto M; Malik TH; Pickering MC
J Am Soc Nephrol; 2016 May; 27(5):1334-42. PubMed ID: 26374608
[TBL] [Abstract][Full Text] [Related]
19. C3 dysregulation due to factor H deficiency is mannan-binding lectin-associated serine proteases (MASP)-1 and MASP-3 independent in vivo.
Ruseva MM; Takahashi M; Fujita T; Pickering MC
Clin Exp Immunol; 2014 Apr; 176(1):84-92. PubMed ID: 24279761
[TBL] [Abstract][Full Text] [Related]
20. Prevention of Fatal C3 Glomerulopathy by Recombinant Complement Receptor of the Ig Superfamily.
Wang X; Van Lookeren Campagne M; Katschke KJ; Gullipalli D; Miwa T; Ueda Y; Wang Y; Palmer M; Xing G; Song WC
J Am Soc Nephrol; 2018 Aug; 29(8):2053-2059. PubMed ID: 29895552
[No Abstract] [Full Text] [Related]
[Next] [New Search]
